New diabetes clinical trial: A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM

Published on: April 08, 2019 at 07:00PM
Condition:   Type II Diabetes Mellitus
Intervention:   Drug: Daily injection of KBP/placebo for up to 28 days
Sponsors:   KeyBioscience AG;   Eli Lilly and Company;   Nordic Bioscience A/S;   Profil Institut für Stoffwechselforschung GmbH
Recruiting